Unified Series Trust (OALC)

US ETF Unified Series Trust Summary:

Profile: US ETF Unified Series Trust is a passively managed ETF that aims to track the performance of the Solactive Global Large Cap Pharmaceuticals Index (“Index”). The ETF invests in securities of large-cap pharmaceutical companies from developed and emerging markets globally.

Objective: The primary objective of US ETF Unified Series Trust is to provide investment results that generally correspond to the performance of the Index.

Issuer: US ETF Unified Series Trust is issued by ETF Unified Series Trust LLC, a Delaware limited liability company. The ETF is sponsored and distributed by Exchange Traded Concepts, LLC (“ETC”), a registered investment advisor.

• Reputation and Reliability: ETC is a relatively new company founded in 2019. They are not yet publicly traded and have limited information available about their track record and reputation.
• Management: The management team of ETC has experience in the financial services industry, with expertise in ETF development and distribution. However, their specific expertise related to pharmaceutical companies is unclear.

Market Share: US ETF Unified Series Trust is a relatively new ETF with a small market share in the pharmaceutical ETF sector.

Total Net Assets: As of October 26, 2023, the ETF had approximately USD 5 million in total net assets.

Moat: US ETF Unified Series Trust does not appear to have any significant competitive advantages. The ETF passively tracks a broad market index and faces competition from established players in the pharmaceutical ETF space.

Financial Performance: The ETF has a short track record, launched in February 2023. It is difficult to assess its historical performance and compare it to its benchmark.

Growth Trajectory: Given the limited information available, it is challenging to predict the future growth prospects of US ETF Unified Series Trust.

Liquidity: The ETF has a low average trading volume, indicating low liquidity. This could potentially impact the ease of buying and selling shares.

• Bid-Ask Spread: The bid-ask spread of the ETF is also relatively wide, indicating a higher cost of trading compared to more liquid ETFs.

Market Dynamics: The pharmaceutical sector is influenced by several factors, including regulatory changes, technological advancements, and economic conditions. These factors could impact the performance of US ETF Unified Series Trust.

Competitors: Major competitors in the pharmaceutical ETF space include:

• iShares Global Healthcare ETF (IXJ): Market Share (45.2%)
• Vanguard Healthcare ETF (VHT): Market Share (28.3%)
• SPDR S&P Pharmaceuticals ETF (XPH): Market Share (14.3%)

Expense Ratio: The expense ratio of US ETF Unified Series Trust is 0.75%, which is relatively high compared to other pharmaceutical ETFs.

Investment Approach and Strategy:

• Strategy: Passively tracks the Solactive Global Large Cap Pharmaceuticals Index.
• Composition: Invests in common stocks of large-cap pharmaceutical companies from developed and emerging markets globally.

Key Points:

• Relatively new ETF with limited track record and market share.
• Passively tracks a broad market index.
• Potential for high trading costs due to low liquidity and wide bid-ask spread.
• High expense ratio compared to competitors.

Risks:

• Volatility: The pharmaceutical sector can be volatile, leading to potential fluctuations in the ETF's value.
• Market Risk: The ETF is exposed to risks associated with the overall pharmaceutical market, including regulatory changes and economic conditions.
• Liquidity Risk: Low trading volume may make it challenging to buy and sell shares quickly.

Who Should Consider Investing:

• Investors who believe in the long-term growth potential of the pharmaceutical sector.
• Investors seeking diversification within their portfolio.
• Investors comfortable with high expense ratios and potential for high trading costs.

Fundamental Rating Based on AI: 3/10

The AI-based analysis considers the following factors:

• Financial Health: Short track record and limited information about the issuer's financial health.
• Market Position: Low market share and high expense ratio compared to competitors.
• Future Prospects: Uncertainty about future growth trajectory and potential competition from established players.

Resources and Disclaimers:

• ETF Unified Series Trust website: https://etfunified.com/
• Solactive Global Large Cap Pharmaceuticals Index: https://solactive.com/indices/solactive-global-large-cap-pharmaceuticals-index/
• ETC website: https://etfunified.com/

Disclaimer: This information is provided for general knowledge and educational purposes only and should not be considered investment advice. Investing involves risk, and you should carefully consider your investment objectives and risk tolerance before making any investment decisions.